Supplemental Materials: Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS)_JAAD
收藏NIAID Data Ecosystem2026-05-01 收录
官方服务：
资源简介：
Supplemental information for the manuscript in the Journal of the American Academy of Dermatology (JAAD): "Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS)"
创建时间：
2023-11-08
